期刊文献+

吡咯列酮对家兔血脂水平的影响及安全性评估

Effection on lipid and drug safety of pioglitazone in rabbits
下载PDF
导出
摘要 目的:探讨吡咯列酮对家兔血脂水平的影响及安全性。方法:将36只新西兰白兔随机分为正常对照组、高胆固醇饮食组、高胆固醇饮食加吡咯列酮组,喂养8周后处死,取兔血清测定血脂、肝功及肾功。结果:高胆固醇饮食组及高胆固醇饮食加吡咯列酮组TC、TG、LDL-C均高于正常对照组,HDL-C水平均低于正常对照组(P<0.05);高胆固醇饮食加吡咯列酮组TG水平低于高胆固醇饮食组,HDL-C高于高胆固醇饮食组(P<0.05)。三组间血清谷丙转氨酶、肌酐水平比较均无显著性差异(P<0.05)。结论:吡格列酮可降低高脂饮食兔血清TG水平,升高高脂饮食兔血清HDL-C水平,对肝肾功能无影响。 Objective: To investigate the effection on lipid and drug safety of pioglitazone in rabbits. Meth- ods: 36 healthy WHHL rabbits were randomly divided into 3 groups: normal control group, high-cholesterol diet group, high-cholesterol diet with pioglitazone group. All animals were feeding for 8 weeks and sacrificed. At the end of the treatment, took rabbits blood to measure lipids, hepatic function and renal function respectively. Results:Ser- um TC, TG, LDL-C in high-cholesterol diet group, high-cholesterol diet with pioglitazone group were higher than in normal control group, HDL-C was lower than normal control group(P〈0.05). In high-cholesterol diet with pioglita- zone group , serum TG was lower comparision to high-cholesterol diet group, HDL-C was higher(P〈0.05). A- mong the 3 groups, there is no significant difference about serum ALT and Cr (P〈0.05). Conclusion: Preventive taking pioglitazone can reduce the elevated TG level and increaseHDL-C level in high-fat diet rabbits, there is no im- pact on hepatic and renal function.
出处 《陕西医学杂志》 CAS 2013年第5期521-522,共2页 Shaanxi Medical Journal
关键词 高脂血症 药物疗法 高脂血症 血液 吡咯烷酮类 治疗应用 胆固醇 代谢 蛋白类 LDL胆固醇 代谢 动物 实验 Hyperlipidemia/drug therapy Hyperlipidemia/blood Pyrrolidinones/therapeutic useCholesterol/metabolism Lipoproteins,LDL cholesterol/metabolism Animals,laboratory Rabbits
  • 相关文献

参考文献6

  • 1Oakes ND, Thalen PG, Jacinio SM, et al. Tesaglitazar, a dual PPAR agonist, ameliorates glucose and lipid intol- erance in obese Zueker rats[J]. Diabetes, 2001, 50 (5) ; 1158-1165.
  • 2Herz M, Johns D, Reviriego J, et al. A randomized, double blind, placebo controlled, clinical trial of the effects of pioglitazone on glycemie control and dyslipi- demia in oral antihyperglyeemie medicationnaive patients with type 2 diabetes mellitus[J]. Clinical Therapeutics, 2003, 25(4) :1074-1095.
  • 3Szymanowski A, Nijm J, Kristenson M ,et al. Elevated levels of circulating matrix metalloproteinase-9 are associ- ated with a dysregulated eortisol rhythm A case-control study of coronary artery disease[J]. Psychoneuroendoeri- nology , 2011, 36 (1):139-143.
  • 4曹茂红,柯开富,周冉冉,周树虎,李秀明.脑梗死患者颈动脉斑块与相关因素分析[J].中华老年心脑血管病杂志,2011,13(1):62-64. 被引量:30
  • 5姚军,郭晓蕙,张俊清,惠岩,陈澜.2型糖尿病患者应用吡格列酮治疗前后血清C反应蛋白的改变[J].中华糖尿病杂志(1006-6187),2005,13(3):209-212. 被引量:22
  • 6Wijk JP, Rabelink TJ. Impact of thiazolidinedione thera- py on atherogenesis[J] Curr Atheroscler Rep, 2005, 7 (5) :369-374.

二级参考文献19

  • 1王薇薇,王新德.第六届全国脑血管病学术会议纪要[J].中华神经科杂志,2004,37(4):346-348. 被引量:300
  • 2许治强,匡永锋,刘子凡,谢亦农,王小莉.颈动脉粥样硬化斑块形成与血清hs-CRP水平变化关系的探讨[J].实用医学杂志,2006,22(7):767-769. 被引量:5
  • 3De Kreutzenberg SV, Tiengo A, Avogaro A. Cerebrovascular disease in diabetes mellitus: The role of carotid intima-media thickness. Nutrition, Metabolism and Cardiovascular Diseases,2009,19:667 -673.
  • 4Nagai Y,Kitagawa K,Sakaguchi M, et al. Significance of earlier carotid atherosclerosis for stroke subtypes. Stroke, 2001, 3:1780 -1785.
  • 5Fukunaga N,Ananb F,Kanedaa K,et al. Lipoprotein(a) as a risk factor for silent cerebral infarction in hemodialysis patients. Metabolism,2008,57 : 1323 -1327.
  • 6Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation, 1997, 96: 1390- 1397.
  • 7Seo W K,Yong HS,Koh SB,et al. Correlation of coronary artery atherosclerosis with atherosclerosis of the intraeranial cerebral artery and the extraeranial carotid artery. Eur Neurol,2008,59:292- 298.
  • 8Kanai A, Kawamura T, Umemura T, et al. Association between future events of brain infarction and soluble levels of intercellular adhesion molecule- 1 and C-reactive protein in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2008,82 : 157- 164.
  • 9Anan F,Sbimomura T,Kaku T,et al. High sensitivity C -reactive protein is a significant risk factor for silent cerebral infarction in patients on hemodialysis. Metabolism, 2008,57 : 66- 70.
  • 10Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prey Rehabit, 2005, 12,243-249.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部